Mice Deficient in Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) are More Susceptible to Retinal Ischemic Injury In Vivo

[1]  H. Vaudry,et al.  PACAP and a novel stable analog protect rat brain from ischemia: Insight into the mechanisms of action , 2011, Peptides.

[2]  A. Tamas,et al.  Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury , 2011, Neuropeptides.

[3]  H. Vaudry,et al.  Neuroprotective Effects of PACAP Against Ethanol-Induced Toxicity in the Developing Rat Cerebellum , 2011, Neurotoxicity Research.

[4]  Yu-ping Peng,et al.  Neuroprotection of Interleukin-6 Against NMDA-Induced Apoptosis and Its Signal-Transduction Mechanisms , 2011, Neurotoxicity Research.

[5]  S. Shioda,et al.  Role of PACAP in neural stem/progenitor cell and astrocyte--from neural development to neural repair. , 2011, Current pharmaceutical design.

[6]  J. Waschek,et al.  Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. , 2011, Current pharmaceutical design.

[7]  A. Tamas,et al.  Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. , 2011, Current pharmaceutical design.

[8]  D. Reglodi,et al.  Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice , 2010, Neuropeptides.

[9]  F. Gallyas,et al.  Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects , 2010, Annals of the New York Academy of Sciences.

[10]  D. Reglodi,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide Deficiency Enhances Oxazolone-Induced Allergic Contact Dermatitis in Mice , 2010, Journal of Molecular Neuroscience.

[11]  D. Reglodi,et al.  Comparison of Intestinal Warm Ischemic Injury in PACAP Knockout and Wild-Type Mice , 2010, Journal of Molecular Neuroscience.

[12]  S. Shioda,et al.  Regulation of Oxidative Stress by Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Mediated by PACAP Receptor , 2010, Journal of Molecular Neuroscience.

[13]  A. Tamas,et al.  Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration , 2010, Brain Research Bulletin.

[14]  K. Nagai,et al.  PACAP-Deficient Mice Exhibit Light Parameter–Dependent Abnormalities on Nonvisual Photoreception and Early Activity Onset , 2010, PloS one.

[15]  A. Tamas,et al.  Novel Neuroprotective Strategies in Ischemic Retinal Lesions , 2010, International journal of molecular sciences.

[16]  M. Tohyama,et al.  Increased Stathmin1 Expression in the Dentate Gyrus of Mice Causes Abnormal Axonal Arborizations , 2010, Neuroscience Research.

[17]  Bodil Gesslein,et al.  The porcine retinal vasculature accessed using an endovascular approach: a new experimental model for retinal ischemia. , 2009, Investigative ophthalmology & visual science.

[18]  H. Vaudry,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery , 2009, Pharmacological Reviews.

[19]  R. Hashimoto,et al.  Depression‐like behavior in the forced swimming test in PACAP‐deficient mice: amelioration by the atypical antipsychotic risperidone , 2009, Journal of neurochemistry.

[20]  T. Bek.  Inner retinal ischaemia: current understanding and needs for further investigations , 2009, Acta ophthalmologica.

[21]  E. Zorrilla,et al.  Urocortin 2 protects against retinal degeneration following bilateral common carotid artery occlusion in the rat , 2009, Neuroscience Letters.

[22]  F. Gallyas,et al.  Protection Against Chronic Hypoperfusion-Induced Retinal Neurodegeneration by PARP Inhibition via Activation of PI-3-kinase Akt Pathway and Suppression of JNK and p38 MAP Kinases , 2009, Neurotoxicity Research.

[23]  A. Tamas,et al.  Effects of Pituitary Adenylate Cyclase Activating Polypeptide and Its Fragments on Retinal Degeneration Induced by Neonatal Monosodium Glutamate Treatment , 2009, Annals of the New York Academy of Sciences.

[24]  J. Waschek,et al.  Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis , 2009, Proceedings of the National Academy of Sciences.

[25]  Tarek A. Shazly,et al.  Neovascular Glaucoma: Etiology, Diagnosis and Prognosis , 2009, Seminars in ophthalmology.

[26]  B. Feigl.  Age-related maculopathy – Linking aetiology and pathophysiological changes to the ischaemia hypothesis , 2008, Progress in Retinal and Eye Research.

[27]  M. Bach,et al.  Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. , 2008, Investigative ophthalmology & visual science.

[28]  K. Nagai,et al.  Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice , 2008, Neuroscience Letters.

[29]  S. Shioda,et al.  Suppression of Ganglion Cell Death by PACAP Following Optic Nerve Transection in the Rat , 2008, Journal of Molecular Neuroscience.

[30]  Takeshi Shimada,et al.  Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. , 2008, Journal of pharmacological sciences.

[31]  S. Shioda,et al.  Role of PACAP in Ischemic Neural Death , 2008, Journal of Molecular Neuroscience.

[32]  J. Waschek,et al.  Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide , 2008, Neuroscience.

[33]  N. Sherwood,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) is important for embryo implantation in mice , 2008, Molecular and Cellular Endocrinology.

[34]  J. Jais,et al.  Novel Mouse Model of Monocular Amaurosis Fugax , 2007, Stroke.

[35]  A. Couvineau,et al.  Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology , 2007, Peptides.

[36]  A. Tamas,et al.  Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. , 2007, General and comparative endocrinology.

[37]  A. Tamas,et al.  Diazoxide is protective in the rat retina against ischemic injury induced by bilateral carotid occlusion and glutamate-induced degeneration , 2007, Neurotoxicity Research.

[38]  F. Gallyas,et al.  Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats , 2007, Neurotoxicity Research.

[39]  H. Vaudry,et al.  Altered cerebellar development in mice lacking pituitary adenylate cyclase‐activating polypeptide , 2007, The European journal of neuroscience.

[40]  F. Bari,et al.  Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases , 2007, Brain Research Reviews.

[41]  F. Gallyas,et al.  The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways , 2006, Regulatory Peptides.

[42]  M. Brownstein,et al.  Neuroprotection by endogenous and exogenous PACAP following stroke , 2006, Regulatory Peptides.

[43]  S. Shioda,et al.  Pleiotropic Functions of PACAP in the CNS , 2006, Annals of the New York Academy of Sciences.

[44]  M. Ozawa,et al.  Neuroprotective Effect of PACAP against Kainic Acid‐Induced Neurotoxicity in Rat Retina , 2006, Annals of the New York Academy of Sciences.

[45]  S. Shioda,et al.  Pituitary adenylate cyclase-activating peptide (PACAP) stimulates production of interleukin-6 in rat Müller cells , 2006, Peptides.

[46]  S. Shioda,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Parel,et al.  Complex neurodegeneration in retina following moderate ischemia induced by bilateral common carotid artery occlusion in Wistar rats. , 2006, Experimental eye research.

[48]  R. Eskay,et al.  Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult , 2005, Peptides.

[49]  A. Tamas,et al.  Effects of PACAP on in vitro and in vivo neuronal cell death, platelet aggregation, and production of reactive oxygen radicals , 2004, Regulatory Peptides.

[50]  A. Tamas,et al.  Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate , 2004, Neuroscience Letters.

[51]  M. Nakata,et al.  PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus , 2004, Neuroscience Letters.

[52]  D. Reglodi,et al.  Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. , 2004, Current pharmaceutical design.

[53]  Richard J. A. Wilson,et al.  Sudden neonatal death in PACAP‐deficient mice is associated with reduced respiratory chemoresponse and susceptibility to apnoea , 2004, The Journal of physiology.

[54]  N. Osborne,et al.  Retinal ischemia: mechanisms of damage and potential therapeutic strategies , 2004, Progress in Retinal and Eye Research.

[55]  H. Hashimoto,et al.  Impaired long-term potentiation in vivo in the dentate gyrus of pituitary adenylate cyclase-activating polypeptide (PACAP) or PACAP type 1 receptor-mutant mice , 2003, Neuroreport.

[56]  A. Tamas,et al.  Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia , 2002, Peptides.

[57]  S. Gray,et al.  Temperature-sensitive phenotype in mice lacking pituitary adenylate cyclase-activating polypeptide. , 2002, Endocrinology.

[58]  J. Waschek.  Multiple Actions of Pituitary Adenylyl Cyclase Activating Peptide in Nervous System Development and Regeneration , 2002, Developmental Neuroscience.

[59]  R. Linden,et al.  Pituitary Adenylyl Cyclase-activating Polypeptide Prevents Induced Cell Death in Retinal Tissue through Activation of Cyclic AMP-dependent Protein Kinase* , 2002, The Journal of Biological Chemistry.

[60]  J. Miyazaki,et al.  Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Shioda,et al.  Gene Expression for PACAP Receptor mRNA in the Rat Retina by in Situ Hybridization and in Situ RT‐PCR , 2000, Annals of the New York Academy of Sciences.

[62]  B. Pappas,et al.  Chronic cerebral hypoperfusion: loss of pupillary reflex, visual impairment and retinal neurodegeneration , 2000, Brain Research.

[63]  S. Shioda,et al.  Electron microscopic observation of pituitary adenylate cyclase-activating polypeptide (PACAP)-containing neurons in the rat retina☆ , 2000, Peptides.

[64]  S. Shioda,et al.  PACAP Protects Hippocampal Neurons against Apoptosis: Involvement of JNK/SAPK Signaling Pathway a , 1998, Annals of the New York Academy of Sciences.

[65]  S. Shioda,et al.  Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina , 1997, Neuroscience Letters.

[66]  J. Hannibal,et al.  Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) in the mesencephalic trigeminal nucleus of the rat after transsection of the masseteric nerve. , 1997, Brain research. Molecular brain research.

[67]  P. Coyle,et al.  Rat Strain and Vendor Differences in Collateral Anastomoses , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[68]  W. Banks,et al.  Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide , 1996, Brain Research.

[69]  F. Sundler,et al.  Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: Up-regulation after peripheral nerve injury , 1996, Neuroscience.

[70]  N. Osborne,et al.  Prolonged bilateral carotid artery occlusion induces electrophysiological and immunohistochemical changes to the rat retina without causing histological damage. , 1995, Experimental eye research.

[71]  M. Culler,et al.  Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. , 1989, Biochemical and biophysical research communications.

[72]  H. Vaudry,et al.  Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. , 2011, Current pharmaceutical design.

[73]  S. Shioda,et al.  Neuroprotective Effect of PACAP Against NMDA-Induced Retinal Damage in the Mouse , 2010, Journal of Molecular Neuroscience.

[74]  S. Shioda,et al.  Suppression of Rat Retinal Ganglion Cell Death by PACAP Following Transient Ischemia Induced by High Intraocular Pressure , 2010, Journal of Molecular Neuroscience.

[75]  A. Tamas,et al.  PACAP Improves Functional Outcome in Excitotoxic Retinal Lesion: An Electroretinographic Study , 2010, Journal of Molecular Neuroscience.

[76]  A. Tamas,et al.  Effects of PACAP in UV-A Radiation-Induced Retinal Degeneration Models in Rats , 2010, Journal of Molecular Neuroscience.

[77]  S. Shioda,et al.  Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. , 2010, Acta neurochirurgica. Supplement.

[78]  M. Vidal-Sanz,et al.  Death and neuroprotection of retinal ganglion cells after different types of injury , 2009, Neurotoxicity Research.

[79]  B. Gong,et al.  Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. , 2007, Investigative ophthalmology & visual science.

[80]  S. Shioda,et al.  Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. , 2006, Annals of the New York Academy of Sciences.